Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy
Bioorganic & Medicinal Chemistry Letters · 2023-10 · 94 · 129458
DOI: 10.1016/j.bmcl.2023.129458 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2023-10. Verfasst von Ryan D Imhoff und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States. Hauptthemen laut MEDLINE: Antimalarials, Deubiquitinating Enzymes, Folic Acid Antagonists, Protozoan Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Malaria continues to be a major burden on global health, responsible for 619,000 deaths in 2021. The causative agent of malaria is the eukaryotic parasite Plasmodium. Resistance to artemisinin-based combination therapies (ACTs), the current first-line treatment for malaria, has emerged in Asia, South America, and more recently Africa, where >90% of all malaria-related deaths occur. This has necessitated the identification and investigation of novel parasite proteins and pathways as antimalarial targets, including components of the ubiquitin proteasome system. Here, we investigate Plasmodium falciparum deubiquitinase ubiquitin C-terminal hydrolase L3 (PfUCHL3) as one such target. We carried out a high-throughput screen with covalent fragments and identified seven scaffolds that selectively inhibit the plasmodial UCHL3, but not human UCHL3 or the closely related human UCHL1. After assessing toxicity in human cells, we identified four promising hits and demonstrated their efficacy against asexual P. falciparum blood stages and P. berghei sporozoite stages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States.
- Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States.
- Department of Microbiology, Biochemistry & Molecular Genetics, Rutgers New Jersey Medical School, Newark, NJ 07103, United States.
- Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, United States; Global Center for Health Security, University of Nebraska Medical Center, Omaha, NE 6…
- Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, IN 47907, United States; Purdue Institute for Drug Discovery, West Lafayette, IN 47907, United States…
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Imhoff, R. D., Rosenthal, M. R., Ashraf, K., Bhanot, P., Ng, C. L., & Flaherty, D. P. (2023). Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy. Bioorganic & Medicinal Chemistry Letters, 94, 129458. https://doi.org/10.1016/j.bmcl.2023.129458
Vancouver
Imhoff RD, Rosenthal MR, Ashraf K, Bhanot P, Ng CL, Flaherty DP. Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy. Bioorganic & Medicinal Chemistry Letters. 2023;94:129458. doi:10.1016/j.bmcl.2023.129458
BibTeX
@article{Imhoff2023,
author = {Imhoff, Ryan D and Rosenthal, Melissa R and Ashraf, Kutub and Bhanot, Purnima and Ng, Caroline L and Flaherty, Daniel P},
title = {Identification of covalent fragment inhibitors for Plasmodium falciparum UCHL3 with anti-malarial efficacy},
journal = {Bioorganic & Medicinal Chemistry Letters},
year = {2023},
volume = {94},
pages = {129458},
doi = {10.1016/j.bmcl.2023.129458}
}
EUVIMED